FDA: NSAID Use Should Be Avoided in Pregnancy Even Sooner Than 30 Weeks
The use of NSAIDs after 20 weeks of pregnancy may lead to low levels of amniotic fluid surrounding the baby resulting in kidney complications.
Obstetrics and Gynecology
Ibrexafungerp NDA for Vulvovaginal Candidiasis Submitted for Review
Ibrexafungerp is an investigational oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.
MPR Weekly Dose Podcast Episode 53
This week: encouraging news on antibody therapies; EUA guidelines for potential vaccines; Remdesivir distribution; The HIV drug that failed to have an impact; And the preterm birth treatment the FDA want withdrawn from the market.
FDA Proposes Makena Be Withdrawn From the Market
Makena received accelerated approval in 2011 to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Modafinil in Early Pregnancy Not Tied to Congenital Malformations
Large birth registry study conducted in Norway and Sweden did not show link to major malformations
MPR Weekly Dose Podcast Episode 50
We cover AstraZeneca’s decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.
Phexxi, a Vaginal pH Regulator, Now Available for Pregnancy Prevention
Phexxi (lactic acid, citric acid and potassium bitartrate; Evofem Biosciences) is the first non-hormonal, on-demand contraceptive vaginal gel.
NAMS 2020 Genitourinary Syndrome of Menopause Position Statement Released
The North American Menopause Society (NAMS) recently announced the publication of its 2020 Genitourinary Syndrome of Menopause (GSM) position statement that included updated recommendations on the most current safe and effective therapeutic options for women with GSM. Despite having a variety of over-the-counter and prescription treatment options, GSM remains underdiagnosed and undertreated. Since the NAMS…
COVID-19 During Pregnancy May Pose Risks for Mother, Baby
Though less likely to report symptoms, pregnant women more likely to need intensive care, ventilation
MPR Weekly Dose Podcast Episode 49
The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there’s developments in convalescent plasma authorization, a 15 minute test, and ethnobotanist’s give a stark warning concerning a plant that some are touting as a cure. In other news an intrauterine device gains expanded approval and there’s a label update for hydrochlorothiazide.
